Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis
| 대상 질환 | Non Alcoholic Steatohepatitis, Fibrosis |
|---|---|
| 임상 단계 | 1/2상 |
| 스폰서 | Stanford University |
| 상태 | 완료 |
| 참여자 수 | 53 명 |
| 중재(약물) | Idebenone |
| 시작일 | 2021년 7월 30일 |
| 완료일 | 2023년 7월 5일 |
| 결과 공개일 | 2026년 3월 27일 |
요약
This is a randomized, placebo-controlled phase 1/2a study to investigate the safety and tolerability of Idebenone in patients 18 years of age or older with non-alcoholic steatohepatitis, with stage 1-3 fibrosis. As secondary end point target engagement and fibrosis improvement will be assessed.
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0
| Idebenone | 9 Participants |
|---|---|
| Placebo | 4 Participants |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatoh — Akero Therapeutics, Inc
- Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Va — Galectin Therapeutics Inc.
- Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease — Wake Forest University Health Sciences
- Effect of Obesity on Proton Pump Inhibitors — Children's Mercy Hospital Kansas City
- Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatoti — Merck Sharp & Dohme LLC
- Phase 2a Study of HPG1860 in Subjects With NASH — Hepagene (Shanghai) Co., Ltd.